SCHEMBL1222362

SCHEMBL1222362

Clc1ccc(CC2(COc3ccc(Cl)c(Cl)c3)CCNCC2)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.54
MAOB P27338 2/20 0.41
SIGMAR1 Q99720 1/20 0.40
SLC6A2 P23975 5/20 0.39
SLC6A4 P31645 5/20 0.39
KCNH2 Q12809 1/20 0.39
SLC6A3 Q01959 2/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1221874 0.90 CHRNA7 (0.47) CHRNA7
SCHEMBL1220797 0.90 CHRNA7 (0.57) CHRNA7
SCHEMBL1222016 0.83 SLC6A2 (0.48) CHRNA7SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL1220771 0.81 CHRNA7 (0.47) CHRNA7SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL1220897 0.81 SLC6A2 (0.50) CHRNA7SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL12586345 0.79 SIGMAR1 (0.44) CHRNA7SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL1221854 0.79 SLC6A2 (0.54) CHRNA7SIGMAR1SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL1220811 0.74 MEN1 (0.41) CHRNA7SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL1220895 0.73 SLC6A2 (0.43) CHRNA7SLC6A2SLC6A4SLC6A3
SCHEMBL15537060 0.72 SLC6A2 (0.49) SIGMAR1SLC6A2SLC6A4KCNH2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046179-A1 NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2011-02-24 US claimed
US-20110046179-A1 NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2011-02-24 US disclosed
EP-2059506-A1 NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-05-20 EP disclosed
WO-2008025777-A1 NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046179-A1 NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC18A3, SLC6A2 CHRNA7 165/4885MAOB 11/4885SIGMAR1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.